Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 1.00 |
| ▸ | MET | P08581 | 12/20 | 0.44 |
| ▸ | LCK | P06239 | 7/20 | 0.44 |
| ▸ | KDR | P35968 | 7/20 | 0.44 |
| ▸ | TEK | Q02763 | 3/20 | 0.44 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523412 | 0.89 | AURKA (0.81) | AURKAMETLCKKDRTEK | |
| SCHEMBL2483272 | 0.80 | AURKA (1.00) | AURKAMETLCKKDRRIPK3 | |
| SCHEMBL17074444 | 0.76 | AURKA (0.80) | AURKAMETLCKKDRRIPK3 | |
| SCHEMBL6530457 | 0.73 | AURKA (0.58) | AURKAMETLCKKDRTEK | |
| SCHEMBL6516115 | 0.70 | AURKA (0.53) | AURKAMETLCKKDRTEK | |
| SCHEMBL12786965 | 0.69 | AURKA (0.62) | AURKAMETLCKKDRRIPK3 | |
| SCHEMBL2484794 | 0.69 | AURKA (1.00) | AURKA | |
| SCHEMBL12786959 | 0.68 | AURKA (0.76) | AURKAMETLCKKDRRIPK3 | |
| SCHEMBL6524050 | 0.68 | KDR (0.64) | METLCKKDRTEK | |
| SCHEMBL23749391 | 0.67 | MET (0.51) | AURKAMETLCKKDRRIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367821-B1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2015-09-16 | — | — | EP | claimed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2367821-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010077530-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | WO | claimed |
| US-9938268-B2 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| US-9938268-B2 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| US-9938268-B2 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010077530-A1 | C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312951-A1 | C-Ring Modified Tricyclic Benzonaphthiridinone Protein Kinase Inhibitors and Use Thereof | PRKCB, PNCK, PACSIN2 | AURKA 562/4885MET 2416/4885LCK 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.